TTrialPathMatch Me to Trials
← Back to trials
RecruitingObstructive Sleep ApneaSleep-disordered Breathing

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

Eligible age

18–79 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Obstructive sleep apnea (OSA) is a common condition in which the airway repeatedly collapses during sleep, leading to poor sleep quality and reduced oxygen levels. Hypoglossal nerve stimulation (HGNS) is an approved treatment that uses a small implanted device to stimulate the genioglossus muscle and keep the airway open. However, some patients continue to have OSA despite using HGNS. Atomoxetine and oxybutynin, "AtoOxy", is a promising pharmacologcal therapy under investigation that has been shown to activate pharyngeal muscles-in particular non-genioglossus muscles--but appears more efficacious in some patients than others. This study will test whether the combination of AtoOxy and HGNS can further improve breathing during sleep compared to either monotherapy alone. Participants with OSA and an HGNS device will be randomized to receive, in random order: HGNS+AtoOxy, HGNS alone (plus placebo), AtoOxy alone (HGNS device off), and placebo (HGNS device off), in a cross-over trial. The main goal is to determine whether the combined treatment reduces the number of breathing events during sleep; the primary outcome test will compare HGNS+AtoOxy versus HGNS alone. The effect of each intervention versus placebo will also be presented. The study will also examine how individual patient characteristics influence response to treatment.

Sponsor: Brigham and Women's Hospital

You may qualify if…

  • ✓ Ages 18 - 79 years
  • ✓ Diagnosed OSA
  • ✓ Implantation of a hypoglossal nerve stimulation device (HGNS, Inspire Medical) or scheduled for implantation (implantation required for randomization)
  • ✓ Willingness to withhold HGNS while testing therapies (up to 6 weeks with HGNS off \[with/without pharmacotherapy\] to assess benefits of HGNS therapy).

You may not qualify if…

  • ✕ Any uncontrolled medical condition
  • ✕ Current use of the medications under investigation.
  • ✕ Issues relating to short-term withdrawal of HGNS therapy
  • ✕ Excluded: Occupational driving (truck drivers, fork-lift operation, taxi/uber drivers)
  • ✕ Excluded: History of traffic accidents attributable to sleepiness or fatigue (\<2 years).
  • ✕ Use of SNRIs/SSRIs or anticholinergic medications during the study.
  • ✕ Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
  • ✕ Respiratory disorders other than sleep disordered breathing:

Where it's recruiting

Source: ClinicalTrials.gov · NCT07577661 · last updated 2026-09-21

Combination Upper-Airway Electrical and Pharmacological Stimulation fo · TrialPath